Gilead SciencesGILD
GILD
About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 18,000
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
194% more first-time investments, than exits
New positions opened: 273 | Existing positions closed: 93
56% more funds holding in top 10
Funds holding in top 10: 18 [Q3] → 28 (+10) [Q4]
14% more capital invested
Capital invested by funds: $86.3B [Q3] → $98.2B (+$11.9B) [Q4]
8% more funds holding
Funds holding: 1,692 [Q3] → 1,833 (+141) [Q4]
2.43% more ownership
Funds ownership: 82.75% [Q3] → 85.18% (+2.43%) [Q4]
10% less call options, than puts
Call options by funds: $864M | Put options by funds: $959M
10% less repeat investments, than reductions
Existing positions increased: 635 | Existing positions reduced: 708
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$90
19%
downside
Avg. target
$119
6%
upside
High target
$140
25%
upside
10 analyst ratings
8 positive
80%
2 neutral
20%
0 negative
0%
JP Morgan Chris Schott 50% 1-year accuracy 8 / 16 met price target | 16%upside $130 | Overweight Maintained | 27 Mar 2025 |
Morgan Stanley Matthew Harrison 46% 1-year accuracy 11 / 24 met price target | 16%upside $130 | Overweight Maintained | 11 Mar 2025 |
B of A Securities Tim Anderson 36% 1-year accuracy 5 / 14 met price target | 13%upside $126 | Buy Maintained | 5 Mar 2025 |
Wells Fargo Mohit Bansal 44% 1-year accuracy 12 / 27 met price target | 25%upside $140 | Overweight Maintained | 5 Mar 2025 |
Oppenheimer Hartaj Singh 26% 1-year accuracy 6 / 23 met price target | 18%upside $132 | Outperform Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 37 articles about GILD published over the past 30 days
Positive
Seeking Alpha
14 hours ago
Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)
We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable income strategy for Options. This monthly series provides two lists of stocks suitable for writing options to generate relatively safe income, focusing on PUT and CALL options.
Negative
Proactive Investors
3 days ago
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Negative
Market Watch
3 days ago
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector.
Negative
Zacks Investment Research
4 days ago
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Neutral
Zacks Investment Research
6 days ago
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.
Positive
Seeking Alpha
1 week ago
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences shows strong growth in its HIV and oncology franchises, with BIKTARVY and TRODELVY driving significant revenue increases in 2024. LIVDELZI's conditional approvals in the U.S. and Europe for PBC treatment could boost the Liver Disease portfolio, despite risks tied to confirmatory trials. SUNLENCA could become the first twice-yearly HIV prevention medication, pending regulatory approvals in the U.S. and Europe, potentially enhancing the HIV franchise.
Negative
Zacks Investment Research
1 week ago
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.
Negative
Zacks Investment Research
1 week ago
GILD Stock Down on Report of Cut in HIV Prevention Spending
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.
Negative
Zacks Investment Research
1 week ago
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Negative
Investors Business Daily
1 week ago
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding
Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline. The post Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding appeared first on Investor's Business Daily.
Charts implemented using Lightweight Charts™